Evidence map›Paper›PMID 39159626›Full record

GuidelineDigestion2025

Evidence-Based Clinical Guidelines for Chronic Constipation 2023.

Eikichi Ihara, Noriaki Manabe, Hidenori Ohkubo, Naotaka Ogasawara, Haruei Ogino, Kazuki Kakimoto, Motoyori Kanazawa, Hidejiro Kawahara, Chika Kusano, Shiko Kuribayashi and 27 more

Abstract readPractice Guideline
In one paragraph

Guideline in Digestion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Medication literacy scale for patients with chronic constipation.Exploratory research in clinical and social pharmacy · 2026
    Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Ileal bile acid transporter inhibitors for chronic constipation in the elderly.World journal of gastrointestinal pharmacology and therapeutics · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Eikichi IharaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Noriaki ManabeGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Hidenori OhkuboGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Naotaka OgasawaraGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Haruei OginoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Kazuki KakimotoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Motoyori KanazawaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Hidejiro KawaharaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Chika KusanoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Shiko KuribayashiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Akinari SawadaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Tomohisa TakagiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Shota TakanoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Toshihiko TomitaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Toshihiro NoakeGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Mariko HojoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Ryota HokariGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Tatsuhiro MasaokaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Tomohiko MachidaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Noboru MisawaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Yoshiyuki MishimaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Hiroshi YajimaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Sayuri YamamotoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Hiroshi YamawakiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Tatsuya AbeGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Yasumi ArakiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Kunio KasugaiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Takeshi KamiyaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Akira ToriiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Atsushi NakajimaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Koji NakadaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Shin FukudoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Yasuhiro FujiwaraGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Hiroto MiwaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Hiromi KataokaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Akihito NagaharaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.
Kazuhide HiguchiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Guidelines for Chronic Constipation 2023, The Japanese Gastroenterological Association, Bunkyo-ku, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Japan Gastroenterological Association published the first version of its clinical guidelines for chronic constipation 2023. Based on the latest evidence, these guidelines describe the definition, classification, diagnostic criteria, diagnostic testing methods, epidemiology, pathophysiology, and treatment of chronic constipation. They include flowcharts for both diagnosis and treatment of chronic constipation. In the treatment of chronic constipation, the first step involves differentiating between secondary forms, such as organic disease-associated constipation, systemic disease-associated constipation, and drug-induced constipation. The next step is to determine whether the chronic constipation stems from a motility disorder, a form of primary chronic constipation. For functional constipation and constipation-predominant irritable bowel syndrome, treatment should be initiated after evaluating symptoms like reduced bowel movement frequency type or defecation difficulty type. The first line of treatment includes the improvement of lifestyle habits and diet therapy. The first drugs to consider for oral treatment are osmotic laxatives. If these are ineffective, secretagogues and ileal bile acid transporter inhibitors are candidates. However, stimulant laxatives are exclusively designated for as-needed use. Probiotics, bulk-forming laxatives, prokinetics, and Kampo medicines, for which there is insufficient evidence, are considered alternative or complementary therapy. Providing the best clinical strategies for chronic constipation therapy in Japan, these clinical guidelines for chronic constipation 2023 should prove useful for its treatment worldwide. The Japan Gastroenterological Association published the first version of its clinical guidelines for chronic constipation 2023. Based on the latest evidence, these guidelines describe the definition, classification, diagnostic criteria, diagnostic testing methods, epidemiology, pathophysiology, and treatment of chronic constipation. They include flowcharts for both diagnosis and treatment of chronic constipation. In the treatment of chronic constipation, the first step involves differentiating between secondary forms, such as organic disease-associated constipation, systemic disease-associated constipation, and drug-induced constipation. The next step is to determine whether the chronic constipation stems from a motility disorder, a form of primary chronic constipation. For functional constipation and constipation-predominant irritable bowel syndrome, treatment should be initiated after evaluating symptoms like reduced bowel movement frequency type or defecation difficulty type. The first line of treatment includes the improvement of lifestyle habits and diet therapy. The first drugs to consider for oral treatment are osmotic laxatives. If these are ineffective, secretagogues and ileal bile acid transporter inhibitors are candidates. However, stimulant laxatives are exclusively designated for as-needed use. Probiotics, bulk-forming laxatives, prokinetics, and Kampo medicines, for which there is insufficient evidence, are considered alternative or complementary therapy. Providing the best clinical strategies for chronic constipation therapy in Japan, these clinical guidelines for chronic constipation 2023 should prove useful for its treatment worldwide.

Indexed as

ConstipationChronic DiseaseEvidence-Based MedicineGastroenterologyHumansJapanLaxativesLaxativesChronic constipationConstipation-predominant irritable bowel syndromeDefinitionFunctional constipationGuidelines

Identifiers

PMID39159626
PMCPMC11825134

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.